Dharti Proteins Limited Files SEBI Compliance Certificate for Q4FY26

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Dharti Proteins Limited filed its mandatory quarterly certificate under SEBI Regulation 74(5) for Q4FY26 ended March 31, 2026. The certificate, confirmed by RTA System Support Services, validates proper dematerialization processes and regulatory compliance. Company Secretary Twinkle Bipinchandra Gajjar submitted the filing to BSE Limited on April 7, 2026, demonstrating adherence to depository regulations.

powered bylight_fuzz_icon
37095397

*this image is generated using AI for illustrative purposes only.

Dharti Proteins Limited (formerly Devika Proteins Limited) has filed its quarterly compliance certificate with BSE Limited for the quarter ended March 31, 2026. The submission fulfills mandatory requirements under SEBI's depository regulations for listed companies.

Regulatory Compliance Filing

The company submitted its certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 on April 7, 2026. Company Secretary and Compliance Officer Twinkle Bipinchandra Gajjar signed the filing on behalf of Dharti Proteins Limited.

Filing Details: Information
Quarter Ended: March 31, 2026
Filing Date: April 7, 2026
Regulation: SEBI Regulation 74(5)
Filed With: BSE Limited
Company Secretary: Twinkle Bipinchandra Gajjar

RTA Confirmation Certificate

System Support Services, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 2, 2026. The RTA confirmed that securities received from depository participants for dematerialization during Q4FY26 were properly processed according to regulatory requirements.

The certificate validates that:

  • Securities received for dematerialization were confirmed to depositories
  • Security certificates were mutilated and cancelled after verification
  • Depository names were substituted in the register of members within the prescribed 30-day period
  • All securities remain listed on stock exchanges where previously issued securities are traded

Company Information

Dharti Proteins Limited operates from its registered office at A-1115, Titanium Business Park, Near Makarba Underpass, Makarba, Ahmedabad. The company maintains its compliance obligations through regular filings with stock exchanges and regulatory authorities.

This quarterly certificate submission represents standard regulatory compliance for listed companies, ensuring transparency in securities handling and depository operations. The filing confirms the company's adherence to SEBI's framework governing depository participants and securities dematerialization processes.

What strategic changes might have prompted Devika Proteins Limited to rebrand as Dharti Proteins Limited?

How will the company's Q4FY26 financial performance compare to previous quarters given the regulatory compliance focus?

What expansion plans does Dharti Proteins have for FY27 from their Ahmedabad operations base?

like20
dislike

Dharti Proteins Limited Reports ₹34.22 Crore Loss in Q3 FY26 Under Resolution Plan

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Dharti Proteins Limited announced Q3 FY26 results showing a net loss of ₹34.22 crores compared to ₹1.16 crores in Q3 FY25, with zero operational revenue. The company operates under NCLT-approved resolution plan with significant shareholding restructuring and has completed newspaper publication compliance under SEBI regulations.

powered bylight_fuzz_icon
35378943

*this image is generated using AI for illustrative purposes only.

Dharti Proteins Limited (formerly Devika Proteins Limited) has announced its unaudited financial results for the quarter and nine months ended December 31, 2025, revealing substantial losses amid ongoing corporate restructuring under insolvency proceedings. The company has also completed newspaper publication of these results in compliance with SEBI regulations.

Financial Performance Overview

The company reported a net loss of ₹34.22 crores for Q3 FY26, significantly higher than the ₹1.16 crore loss recorded in Q3 FY25. The company generated no revenue from operations during the quarter, with other income of ₹0.44 lakhs being the only source of income.

Financial Metric: Q3 FY26 Q3 FY25 Change (%)
Revenue from Operations: - - -
Other Income: ₹0.44 lakhs ₹2.21 lakhs -80.09%
Total Revenue: ₹0.44 lakhs ₹2.21 lakhs -80.09%
Net Loss: ₹34.22 crores ₹1.16 crores -2,850.00%
Basic EPS: ₹(0.33) ₹(0.01) -

Nine-Month Performance

For the nine months ended December 31, 2025, the company's financial position deteriorated further. The net loss expanded to ₹39.24 crores compared to ₹2.82 crores in the corresponding period of the previous year. Other income for the nine-month period stood at ₹2.93 lakhs against ₹2.43 lakhs in the previous year.

Nine-Month Metrics: FY26 FY25 Change (%)
Other Income: ₹2.93 lakhs ₹2.43 lakhs +20.58%
Total Expenses: ₹11.33 lakhs ₹5.25 lakhs +115.81%
Net Loss: ₹39.24 crores ₹2.82 crores -1,291.49%

Corporate Restructuring Under NCLT

The company is operating under a Corporate Insolvency Resolution Process (CIRP) following an order dated November 18, 2025, by the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench. The resolution plan submitted by Mr. Jatinbhai Ramanbhai Patel has been approved, bringing significant changes to the shareholding structure.

Under the approved resolution plan:

  • Existing public shareholding reduced to 25,000 equity shares
  • 50,000 equity shares of ₹10 each proposed for allotment to Financial Creditors
  • 4,25,000 equity shares of ₹10 each proposed for allotment to the Successful Resolution Applicant and promoter group

SEBI Compliance and Publication

In accordance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has published its standalone unaudited financial results in "Financial Express" in both English and Gujarati languages on March 19, 2026. The newspaper publication was communicated to BSE through a formal compliance letter signed by Company Secretary and Compliance Officer Twinkle Bipinchandra Gajjar.

Auditor Qualifications

The company's statutory auditors, N.S. Nanavati & Co., issued a qualified opinion on the financial results, highlighting several concerns:

  • Going Concern Issues: Company has been inoperative for several years with no trading or manufacturing activities
  • MSMED Act Compliance: Inability to determine compliance with delayed payment provisions
  • Loans and Advances: Outstanding balance of ₹150.46 lakhs with minimal recovery prospects
  • Asset Verification: Concerns regarding accuracy and existence of other current assets and liabilities

Key Financial Indicators

The company's financial position reflects significant distress with total assets of ₹232.53 lakhs against total liabilities of ₹378.95 lakhs, resulting in a negative net worth of ₹146.42 lakhs. The paid-up equity share capital remains at ₹1,027.72 lakhs with face value of ₹10 per share.

Financial Position: Amount (₹ Lakhs)
Total Assets: 232.53
Total Liabilities: 378.95
Net Worth: (146.42)
Paid-up Equity Capital: 1,027.72

The Board of Directors approved these financial results at their meeting held on March 18, 2026, with the effects of the resolution plan to be reflected in the financial results for the quarter ending March 31, 2026.

How will the implementation of Mr. Jatinbhai Ramanbhai Patel's resolution plan impact the company's operational revival and future business strategy?

What are the prospects for existing minority shareholders given the significant dilution from the new equity allotments under the CIRP?

Will Dharti Proteins be able to resume manufacturing operations and generate revenue in FY27 following the completion of the insolvency resolution process?

like19
dislike

More News on Dharti Proteins Limited